arrow
G

Giuseppe Pietrantuono

IRCCS CROB
H指数:28
被引数:3,025

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

多发性骨髓瘤患者在来那度胺维持治疗后进展的挽救治疗模式:欧洲骨髓瘤网络(EMN)意大利的真实世界研究

2026-09-050
OAAI
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial

自体移植后复发/难治性滤泡性淋巴瘤患者继发恶性肿瘤风险增加:FIL-FLAZ12 III期试验的长期结果

2026-08-120
OAAI
Complex genetic landscape in CLL: Clinical impact on patients' survival and insights into the altered molecular pathways

CLL中复杂的遗传景观:对患者的生存影响的临床意义以及对改变分子通路的见解

2025-09-010
OAAI
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy

临床医生对荧光原位杂交技术(FISH)定义多发性骨髓瘤细胞遗传学风险的观点与方法学应用:欧洲骨髓瘤网络(EMN)意大利分会基于真实世界调查的报告

2025-03-290
OAAI
Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia: Observational Study of 673 Patients in Italy

酪氨酸激酶抑制剂在慢性髓性白血病中的停药:意大利673例患者的观察性研究

BLOOD
IF23.1
2024-11-050
PRE
Treatment-Free Remission in CML Patients Discontinuing Post-First Line Therapy

停用一线治疗后慢性粒细胞白血病患者中的无治疗缓解

BLOOD
IF23.1
2024-11-050
PRE
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

del(5q) 骨髓增生异常肿瘤患者停用来那度胺后的输血独立性: HARMONY Alliance研究

LEUKEMIA
IF13.4
2024-08-050
OA
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells
2024-06-071
OAAI
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
2024-02-220
OAAI
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
2022-06-0111
OA
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience
2021-11-017
OAAI
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
2021-08-2613
OAAI
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
2020-10-0638
OAAI